Idioma:

Gut Microbiome and Organ Fibrosis

Costa, Carolina F F A ; Sampaio-Maia, Benedita ; Araujo, Ricardo ; Nascimento, Diana S ; Ferreira-Gomes, Joana ; Pestana, Manuel ; Azevedo, Maria J ; Alencastre, Ines S

Nutrients, 2022-01, Vol.14 (2), p.352 [Periódico revisado por pares]

Switzerland: MDPI AG

Texto completo disponível

Citações Citado por

Enviar para

Título:
Gut Microbiome and Organ Fibrosis
Autor: Costa, Carolina F F A ; Sampaio-Maia, Benedita ; Araujo, Ricardo ; Nascimento, Diana S ; Ferreira-Gomes, Joana ; Pestana, Manuel ; Azevedo, Maria J ; Alencastre, Ines S
Assuntos: Adaptive systems ; Bacteria ; Cardiovascular diseases ; Cirrhosis ; Collagen ; Crosstalk ; Digestive system ; Digestive tract ; Disease ; Dysbacteriosis ; Dysbiosis - microbiology ; Dysbiosis - pathology ; Extracellular matrix ; Fibroblasts ; Fibrosis ; Fibrosis - microbiology ; Gastrointestinal Microbiome ; Growth factors ; gut microbiome ; heart fibrosis ; Humans ; Immune system ; Inflammation ; Inflammatory bowel disease ; Inflammatory diseases ; intestinal fibrosis ; Intestinal microflora ; Intestine ; Kidney diseases ; kidney fibrosis ; Liver cirrhosis ; Liver diseases ; liver fibrosis ; lung fibrosis ; Microbiomes ; Microbiota ; Morbidity ; Pathogenesis ; Pathogens ; Review ; Smooth muscle ; Therapeutic targets ; Tumor necrosis factor-TNF
É parte de: Nutrients, 2022-01, Vol.14 (2), p.352
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Fibrosis is a pathological process associated with most chronic inflammatory diseases. It is defined by an excessive deposition of extracellular matrix proteins and can affect nearly every tissue and organ system in the body. Fibroproliferative diseases, such as intestinal fibrosis, liver cirrhosis, progressive kidney disease and cardiovascular disease, often lead to severe organ damage and are a leading cause of morbidity and mortality worldwide, for which there are currently no effective therapies available. In the past decade, a growing body of evidence has highlighted the gut microbiome as a major player in the regulation of the innate and adaptive immune system, with severe implications in the pathogenesis of multiple immune-mediated disorders. Gut microbiota dysbiosis has been associated with the development and progression of fibrotic processes in various organs and is predicted to be a potential therapeutic target for fibrosis management. In this review we summarize the state of the art concerning the crosstalk between intestinal microbiota and organ fibrosis, address the relevance of diet in different fibrotic diseases and discuss gut microbiome-targeted therapeutic approaches that are current being explored.
Editor: Switzerland: MDPI AG
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Gut Microbiome and Organ Fibrosis

Costa, Carolina F F A ; Sampaio-Maia, Benedita ; Araujo, Ricardo ; Nascimento, Diana S ; Ferreira-Gomes, Joana ; Pestana, Manuel ; Azevedo, Maria J ; Alencastre, Ines S

Switzerland: MDPI AG

Buscando em bases de dados remotas. Favor aguardar.